| Similar Articles |
|---|
 |
The Motley Fool
December 30, 2003
Tom Taulli |
M&A As Strong Medicine Invitrogen's latest deal shows that the company knows where its market is headed.   |
Bio-IT World
November 2005 |
News Blast Invitrogen has acquired Quantum Dot Corp and BioPixels... CombinatoRX and Angiotech Pharmaceuticals strike an agreement... Caliper Life Sciences to close NovaScreen BioSciences... Rosetta Biosoftware and Agendia working together... |
Bio-IT World
December 15, 2003
Malorye A. Branca |
Scenes from a Cell Breakthroughs are making cell-based screening faster, easier, more powerful. |
The Motley Fool
November 30, 2010
Brian Orelli |
RNAi Is On Sale The novel technology looks more promising at these prices. |
Bio-IT World
March 2006 |
Bio-IT World Bio-IT 50 The 50 companies profiled here have driven and continue to drive the future of biomedical research and drug discovery: Accelrys... Affymetrix.. Apple... Becton Dickinson... BlueArc... 454 Life Sciences... etc. |
Bio-IT World
September 2005
Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. |
Bio-IT World
July 15, 2003
Malorye Branca |
Silence Is Golden RNA interference's scientific, therapeutic, and economic potential is unquestionable, but some sticky questions still remain. |
The Motley Fool
August 14, 2007
Brian Orelli |
Drugmaker Growth Without the FDA Do you have one of those stomachs that just can't take the ups and downs of clinical trial data and FDA approval decisions? Buy stocks in the companies that support the drug makers. |
Bio-IT World
November 14, 2003
Hoffer et al. |
Over the Rainbow Yet? Consolidation slows, valuations grow, and now there's hope for some biotech IPOs. |
Bio-IT World
July 2005 |
News Blast On the Label... Brain Gain... Turbo Works... New Pathways... etc. |
Bio-IT World
December 15, 2004
William Marshall |
Applications of RNAi RNA interference is a highly coordinated gene regulatory mechanism that appears to be highly conserved across all metazoans studied thus far. |
The Motley Fool
February 7, 2008
Brian Orelli |
Invitrogen Integrates After a rough 2006 in which it struggled to integrate its acquisitions, Invitrogen used 2007 to show why it made all of its purchases. |
Bio-IT World
November 2005
Nancy Weil |
Dharmacon, Institutes Form siRNA Global Initiative The company has formed a global alliance with leading biomedical research centers aimed at speeding scientific and medical discoveries now that the first complete siRNA (small interfering RNA) library is available for targeting genes in the human genome. |
Bio-IT World
December 15, 2004
Nancy Weil |
Running Interference The revolution in RNA interference has galvanized basic research. Now, some biopharmas are pushing the technology from the laboratory to the clinic. |
Bio-IT World
November 19, 2004
Hoffer & Nambiar |
Mirus Index Heads South Overall, companies in the Mirus Index declined in the third quarter of 2004. |
Bio-IT World
December 15, 2004
David A. Bumcrot |
Identifying RNAi Drug Candidates Breakthroughs in understanding RNA's extensive role in essential cellular processes have opened up the potential for a whole new class of drugs based on RNAi. |
Bio-IT World
August 2005
Maureen McDonough |
Invitrogen Launches iPath Invitrogen has unveiled a free bioinformatics and systems biology research tool that can be found on the company's Web site. iPath allows users to click their way through 2,500 human genes, 171 signal transduction pathways, and 54 metabolic pathways. |
The Motley Fool
September 28, 2006
Ralph Casale |
A Second Sell-Off at Molecular Devices The company, which makes equipment used in drug development, is struggling with lumpy revenues. |
Bio-IT World
November 2005
Robert M. Frederickson |
Innovations in Interference RNAi has moved from phenomenon to promising drug in less than five years, but it also has potential to be a tool used in drug discovery. |
Bio-IT World
August 18, 2004 |
Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated. |
Bio-IT World
May 9, 2003
Malorye Branca |
Discovering the Joy of Cannibalism Persistent financial pressures feed continuing consolidation among struggling genomics companies |
Bio-IT World
December 15, 2004
Zachary Zimmerman |
Silence Is Golden Life Science Insights believes that RNAi therapeutics will dramatically affect the pharmaceutical and healthcare industries, becoming the next major class of therapeutics, joining small molecules, proteins, and monoclonal antibodies. |
